IMPACT for East Midlands – 25th January

by

Pelican Cancer Foundation invites MDT members to join us at our East Midlands IMPACT workshop on 25th January 2019. This event will be held at The Raddison Blu East Midlands Airport Hotel. We offer 7 free places per MDT, any additional places will be charged at £95 per person. Unfortunately, we are unable to accept individual registrations.

Pelican IMPACT programme E Midlands

To book your place, please return your IMPACT Booking Form to courses@pelicancancer.org 

Alternatively – you can post it to us at:

Pelican Cancer Foundation

The Ark, Dinwoodie Drive

Basingstoke

RG24 9NN

We look forward to seeing you there!

London Marathon 2018 – Sima Lowery

by

Sima decided to take on the challenge of marathon training in the winter to run the London Marathon. Running in memory of her father-in law, Eddie Lowery, who fought bowel cancer with great courage and dignity 5 years ago, Sima also ran the marathon for her family in the North East, Yorkshire, UK, Iran, Dubai, and USA. Sima’s Dad has also embarked on his own journey to fight bowel cancer.
Sima smashed her target and raised a total of £1,694.13 for Pelican. Thank you Sima for this amazing achievement!

Jonathan – London Marathon 2018

by

Jonathan took his trainers out of retirement to run the 2018 London Marathon for Pelican Cancer Foundation. His colleague Tony, has been fighting bowel cancer for almost two years and so Jonathan decided to fundraise to help the charity continue their work in helping Tony and others like him battle this awful disease.

Jonathan has raised a fantastic total of £1,738.75 for Pelican and we are incredibly grateful to him for all his hard work in completing the marathon.

Sign up to hear more from us

by

We really like to stay in touch with all of our supporters. Please sign up below to hear more about the latest news, events and ground breaking work from Pelican Cancer Foundation.

 

Programmes – IMPACT

by

Please see below for IMPACT course programmes for 2018.

Basingstoke: 26th January 2018 IMPACT programmeBasingstoke

Yorkshire: 21st March 2018 IMPACTprogramme York

Scotland: 2nd May 2018 IMPACTprogramme Edinburgh

Newcastle: 17th September 2018 Pelican IMPACT draft programme 17.9.18 Newcastle NV

Greater Manchester: 23rd November 2018 V.2 Draft programme for IMPACT Manchester.pdf

Ireland: 10th December 2018 V.1 CO Draft programme for IMPACT Ireland.pdf

East Midlands (Derby): 25th January V.2 SR Draft programme for IMPACT E Midlands.pdf

 

 

Key messages from the faculty

by

IMPACT: 25th January 2019/Derby

Colorectal Liver Metastases

  1. All patients with colorectal liver metastases should be discussed in a specialist hepatobiliary MDT
  2. All patients should have the results of their assessment and follow up scans as swiftly as possible, ideally the same day, acknowledging the significant anxiety experienced by patients at the time of a scan
  3. Pre-operative chemotherapy should be given for the minimum number of cycles required to achieve resectability, to avoid chemotherapy-associated liver injury
  4. Any liver resection should be parenchymal-sparing, to preserve liver volume and allow further interventions for recurrent disease
  5. All resected patients should be entered into a CT surveillance programme. Patients whose liver metastases have disappeared with chemotherapy will require more intensive surveillance, for a longer period of time
  6. Molecular testing should be carried out prior to anti-EGFR treatment using an extended RAS panel (KRAS 12/13/59/61/117/146 and NRAS 12/13/59/61) and thought should be given as to which sample is most appropriate to test e.g. biopsy, resection, metastasis. Multiple blocks should be tested together from larger specimens to maximise the chances of finding a mutation.
  7. Mismatch repair status should be available in all cases either by immunohistochemistry or MSI, in line with NICE guidance DG27.

Colorectal Lung Metastases

  1. Criteria for consideration of pulmonary metastasectomy of colorectal disease: control of primary, radically treatable oligometastastic disease, resectable disease, sufficient pulmonary reserve, disease stability
  2. Favourable prognostic features in patients undergoing pulmonary metastasectomy: longer disease free interval (< 1 year vs. >3 years), number of metastasis, complete resection, lack of nodal involvement
  3. Factors of uncertain prognostic importance: CEA level, tumour doubling time, histopathological markers, re-operation
  4. Investigate the possibility of a primary lung cancer rather than metastasis. Tissue morphological diagnosis is required to interpret molecular biomarkers.

Colorectal Peritoneal Metastases

  1. Best outcomes: Limited disease PCI <20, favourable biology (differentiation, time to recurrence), response to adjuvant or neo adjuvant chemotherapy, complete cytoreduction
  2. Effective and regular communication is helpful with patients; between units; and between teams
  3. A clear understanding by patient and local teams that the pathway is often lengthy (approx. 3 months) requiring repeated investigations and assessments during which time interaction with key workers is essential

Locally advanced or recurrent colorectal cancer

  1. Management of locally recurrent CRC is an MTE – Massive Team Endeavour: Referring team and MDT; receiving team and MDT; CNSs; Medical and clinical oncology; Palliative care; Radiology; IR; Pathology; Anaesthetics; different surgical specialties; medical physics and radiographers
  2. No clear single model or pathway: Tailored to individual patients; anatomy, classification of disease, and circumstances
  3. General oversight by specialist MDT where possible
  4. Early review and discussion between the planned ultimate surgical team and patients and their family is encouraged

Palliative Care

  1. Significant numbers of patients will have a reduced life expectancy and problematic symptoms. A study in 2016 showed that the most frequent symptoms reported are Worrying 65%; Lack of energy 59%; Drowsiness 54%; Bloated 53%; Pain 51; Insomnia 50%; the most severe are problems with sexual interest & loss of appetite.
  2. A study in 2017 showed that patients perceive they have unmet needs. These are predominantly psychological: fear of spread; worry about family; lack of control; anxiety; uncertainty; death & dying; depression; keeping positive. Over 50% had at least one psychological need.
  3. MDTs will see benefit if palliative care colleagues are fully integrated members of their MDT and service. Consider referring patients to palliative care early if they have metastatic or locally advanced disease. This can occur alongside other treatment processes and patients respond well to seeing a Palliative Medicine consultant in a hospital clinic.

IMPACT: 21st March/Yorkshire

Palliative Care

  1. Significant numbers of patients will have a reduced life expectancy and problematic symptoms: Most severe symptoms = problems with sexual interest & loss of appetite
  2. Patients perceive that they have unmet needs: fear of spread; worry about family; lack of control; anxiety; uncertainty; death & dying; depression; keeping positive. Over 50% had at least one psychological need. Association between perceived need psychological distress & QoL
  3. When to refer for palliative care / enhanced supportive care: Early palliative care group had higher QoL at 14 weeks, less depression, more had documented DNAR order, less late (within 14 days of death) chemotherapy. Significantly longer median survival (2.7 months)

Colorectal Liver Metastases

  1. All patients with colorectal liver metastases should be discussed in a specialist hepatobiliary MDT
  2. All patients should have the results of their assessment and follow up scans as swiftly as possible, ideally the same day, acknowledging the significant anxiety experienced by patients at the time of a scan
  3. Pre-operative chemotherapy should be given for the minimum number of cycles required to achieve resectability, to avoid chemotherapy-associated liver injury
  4. Any liver resection should be parenchymal-sparing, to preserve liver volume and allow further interventions for recurrent disease
  5. All resected patients should be entered into a CT surveillance programme. Patients whose liver metastases have disappeared with chemotherapy will require more intensive surveillance, for a longer period of time

Colorectal Lung Metastases

  1. Criteria for consideration of pulmonary metastasectomy of colorectal disease: control of primary, radically treatable oligometastastic disease, resectable disease, sufficient pulmonary reserve, disease stability
  2. Favourable prognostic features in patients undergoing pulmonary metastasectomy: longer disease free interval (< 1 year vs. >3 years), number of metastasis, complete resection, lack of nodal involvement
  3. Factors of uncertain prognostic importance: CEA level, tumour doubling time, histopathological markers, re-operation

Colorectal Peritoneal Metastases

  1. Best outcomes: Limited disease PCI <20, favourable biology (differentiation, time to recurrence), response to adjuvant or neo adjuvant chemotherapy, complete cytoreduction

Locally advanced or recurrent colorectal cancer

  1. Management of locally recurrent CRC is an MTE – Massive Team Endeavour: Referring team and MDT; receiving team and MDT; CNSs; Medical and clinical oncology; Palliative care; Radiology; IR; Pathology; Anaesthetics; different surgical specialties; medical physics and radiographers
  2. Communication challenges: Effective and regular communication is helpful with patients; between units; and between teams
  3. A clear understanding by patient and local teams that the pathway is often lengthy (approx. 3 months) requiring repeated investigations and assessments during which time interaction with key workers is essential
  4. No clear single model or pathway: Tailored to individual patients; anatomy, classification of disease, and circumstances
  5. General oversight by specialist MDT where possible
  6. Early review and discussion between the planned ultimate surgical team and patients and their family is encouraged

IMPACT: 26th January/Basingstoke

Colorectal liver metastases

Colorectal lung metastases ColorectalLung Metastases IMPACT EB v2

Colorectal peritoneal metastases Peritoneal Metastases IMPACT January FM

Colorectal peritoneal metastases Peritoneal Metastases IMPACT2

Colorectal peritoneal metastases Colorectal peritoneal metastases IMPACT pathology NC3

Locally advanced and recurrent colorectal cancer Locally recurrent CRC AHM

Palliative Care in Colorectal Cancer Palliative Care in colorectal cancer – IMPACT 1LB

Pathology IMPACT Pathology

Key papers – IMPACT

by

Colorectal Liver Metastases

Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial. Ruers T, Van Coevorden F, Punt CJ, Pierie JE, Borel-Rinkes I, Ledermann JA, Poston G, Bechstein W, Lentz MA, Mauer M, Folprecht G, Van Cutsem E, Ducreux M, Nordlinger B; European Organisation for Research and Treatment of Cancer (EORTC); Gastro-Intestinal Tract Cancer Group; Arbeitsgruppe Lebermetastasen und tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); National Cancer Research Institute Colorectal Clinical Study Group (NCRI CCSG).

RE: Local Treatment of Unresectable Colorectal Liver Metastases: Results of a RandomizedPhase II Trial. Macbeth F, Farewell V, Treasure T.

Progress and future direction in the management of advanced colorectal cancer G. M. Brown, M. J. Solomon First published: 13 April 2018

NICE Colorectal Cancer Quality Standard 20 [QS20], published August 2012

NICE guidance – Colorectal cancer: diagnosis and management (CG131), Last updated December 2014

Randomised multicentre trial of gadoxetic acid-enhanced MRI vs conventional MRI or CT in the staging of colorectal liver metastases, Zech CJ et al. British Journal of Surgery 2014, 101:613-21

Chemotherapy before liver resection of colorectal metastases – friend or foe? Lehmann K, Rickenbacher A, Weber A, Pestalozzi BC, Clavien PA. Annals of Surgery 2012, 255(2): 237-47.

One-millimeter cancer-free margin is curative for colorectal liver metastases: a propensity score case-match approach. Hamady ZZ, Lodge JP, Welsh FK, Toogood GJ, White A, John TG,. Rees M. Annals of Surgery 2014; 259(3):543-8.

Patient-reported outcomes after hepatic resection of colorectal liver metastases. Rees JR, Blazeby JM, Fayers P, Friend EA, Welsh FK, John TG, Rees M. J Clinical Oncology 2012; 30(12):1364-70.

Stereotactic body radiotherapy for liver metastases. Aitken KL, Hawkins MA, Clin Oncol (R Coll Radiol) 2015, 27(5):307-15

Impact of hepatobiliary service centralization on treatment and outcomes in patients with colorectal cancer and liver metastases  E. Vallance  J. vanderMeulen  A. Kuryba  I. D. Botterill  J. Hill  D. G. Jayne  K. Walker

First published: 2 March 2017 https://doi.org/10.1002/bjs.10501

Cited by: 2 https://onlinelibrary.wiley.com/doi/full/10.1002/bjs.10501

Colorectal Lung Metastases

Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566patients with 1037 metastases. de Baère T, Aupérin A, Deschamps F, Chevallier P, Gaubert Y, Boige V, Fonck M, Escudier B, Palussiére J.

Survival after radiofrequency ablation in 122 patients with inoperable colorectal lung metastases. de Baère T, Aupérin A, Deschamps F, Chevallier P, Gaubert Y, Boige V, Fonck M, Escudier B, Palussiére J.

Systematic review and meta-analysis – Gonzalez et al., Annals of Surgical Oncology 2013;20:572-9
2925 patients 25 studies, 27%-68% OS 5 years.

Pasturino U, Buyse M, Friedel G, et al., Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg. 1997 Jan;113(1):37-49.

Gonzalez M, Poncet A Combescure C et al., Risk Factors for survival after lung metastasectomy in colorectal cancer patients: systematic review and meta-analysis.  Ann Surg Oncol. 2013 Feb;20(2):572-9.

Surgery and ablative techniques for lung metastases in the Pulmonary Metastasectomy in Colorectal Cancer (PulMiCC) trial: is there equivalence? Treasure T et a., J Thorac Dis. 2016.

Prognostic factors after pulmonary metastasectomy of colorectal cancers: a single centre experience. Fournel L et al. J Thorac Dis. 2017.

Pulmonary metastasectomy: an overview Petrella F et al., J Thorac Dis 2017.

 

Pathology

Molecular testing key papers:

https://www.nice.org.uk/guidance/dg27

Molecular testing in advanced/metastatic disease

RAS testing of colorectal carcinoma—a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group

Newton ACS Wong1, David Gonzalez2, Manuel Salto-Tellez3, Rachel Butler4, Salvador J Diaz-Cano5, Mohammad Ilyas6, William Newman7, Emily Shaw8, Philippe Taniere9, Shaun V Walsh10

Standards for integrated reporting in cellular pathology January 2017

Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing. Richman SD1, Chambers P, Seymour MT, Daly C, Grant S, Hemmings G, Quirke P.

Annual Report of the Chief Medical Officers 2016

Colorectal Peritoneal Metastases

Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. Verwaal VJ1, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, Zoetmulder FA.

Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. Elias D1, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, Lorimier G, Dubè P, Glehen O.

Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone R Mirnezami, A M Mehta, K Chandrakumaran, T Cecil, B J Moran, N Carr, V J Verwaal, F Mohamed & A H Mirnezami

Peritoneal metastases of lower GI tract origin… Ung L:  J Cancer Res Clin Oncol 2013; 139:1899-1908

Peritoneal carcinomatosis of colorectal cancer… Massalou D: American Journal of Surgery 2017; 213:377-87

External validation of models predicting the individual risk of metachronous peritoneal carcinomatosis from colon and rectal cancer. Segelman J: Colorectal Dis 2015; 18:378-85.

NICE guidance IPG 331 Cytoreduction surgery followed by hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis Feb 2010

NHS Commissioning A08/P/a  Cytoreduction surgery for patients with peritoneal carcinomatosis April 3013

Impact of surgical volume of centers on post-operative outcomes from cytoreductive surgery and hyperthermic intra-peritoneal chemoperfusion. Rahul Rajeev, Brittany Klooster, and Kiran K. Turag J Gastrointest Oncol. 2016 Feb; 7(1): 122–128

A Systematic Review and Meta-Analysis of Cytoreductive Surgery with Perioperative Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colorectal Origin. Cao C, Yan TD, Black D, Morris DL. Ann Surg Oncol. 2009 Aug 12;16(8):2152–65

Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Franko J, Shi Q, Meyers JP, Maughan TS, Adams RA, Seymour MT, et al.  Lancet Oncol. 2016;17(12):1709–19

Local Recurrence

Increased local recurrence and reduced survival from colorectal cancer following anastomotic leak: systematic review and meta-analysis. Mirnezami A, Mirnezami R, Chandrakumaran K, Sasapu K, Sagar P, Finan P.  Ann Surg. 2011 May;253(5):890-9.

Factors affecting outcomes following pelvic exenteration for locally recurrent rectal cancer. PelvEx Collaborators (83)

Anastomotic Leaks After Restorative Resections for Rectal Cancer Compromise Cancer Outcomes and Survival. Lu ZR, Rajendran N, Lynch AC, Heriot AG, Warrier SK. Dis Colon Rectum. 2016 Mar;59(3):236-44.

Beyond TME Collaborative. Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes. Br J Surg. 2013 Jul;100(8):1009-14.

Beyond TME Collaborative. Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes. Br J Surg. 2013 Jul;100(8):E1-33.

Other papers collected by Pelican

The Fundamental Difference Between Cancer Treatment and Patient Care

Advances in surgical management for locally recurrent rectal cancer: How far have we come? Daniel Jin-Keat Lee, Peter M Sagar, Gaitri Sadadcharam, and Kok-Yang Tan
World J Gastroenterol. 2017 Jun 21; 23(23): 4170–4180.

Effect of specialist decision-making on treatment strategies for colorectal liver metastases Jones RP1, Vauthey JN, Adam R, Rees M, Berry D, Jackson R, Grimes N, Fenwick SW, Poston GJ, Malik HZ.  Br J Surg. 2012 Nov;99(11):1605

Large variation in the utilization of liver resections in stage IV colorectal cancer patients with metastases confined to the liver AlibR.H.A.VerhoevencR.M.H. Roumend V.E.P.P. LemmenscA.M.Rijkenb, J.H.W.De Wilta

European Journal of Surgical Oncology (EJSO) Volume 41, Issue 9, September 2015, Pages 1217-1225

Regional and inter-hospital differences in the utilisation of liver surgery for patients with synchronous colorectal liver metastases in the Netherlands Lam-BoeraE.P. van der StokbJ. HuiskenscR.H.A., VerhoevendC.J.A., PunteM.A.G.,  ElferinkdJ.H, de WiltaC.Verhoefb

the CAIRO5/CHARISMA Group1
European Journal of Cancer Volume 71, January 2017, Pages 109-116

Treatment of colorectal peritoneal metastases requires multidisciplinary efforts Diane Goéré, Maximiliano Gelli

Lancet Oncology  Volume 17, No. 12, p1630–1631, December 2016

Onco-Surgical Management of Liver Metastases from Colorectal Cancer

Population-based study on resection rates and survival in patients with colorectal liver metastasis in Norway J.-H. Angelsen, A. Horn,  Sorbye,  G. E. Eide, I. M. Løes, A. Viste
BJS First published: 9 February 2017 DOI: 10.1002/bjs.10457

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: from novelty to routine in selected cases – B Moran.
Techniques in Coloproctology. September 2017, Volume 21, Issue 9, pp 767–769 | Cite as

 

 

 

 

IMPACT for Northern Ireland/Republic of Ireland – 10th December

by

Pelican Cancer Foundation invites MDT members to join us at our IMPACT workshop on 10th December. To be held at the Catherine McAuley Centre, Mater Hospital, Dublin. We offer 7 free places per MDT, any additional places will be charged at £95 per person. Unfortunately, we are unable to accept individual registrations.

To book your place, please return your IMPACT Booking Form to courses@pelicancancer.org 

Alternatively – you can post it to us at:

Pelican Cancer Foundation

The Ark, Dinwoodie Drive

Basingstoke

RG24 9NN

We look forward to seeing you there!

Pelican Cancer Foundation – Who we are

by

We drive innovation and development in bowel (colorectal), bladder, prostate and liver cancer treatment through research and education, and advancing precision surgery and treatment. So – our message is different. Our focus is on surgery, which provides the best outcomes and is often neglected.

Please have a look at our video: Pelican Cancer Foundation 2018 – Who we are. This is about what we do, our research, and how we are working towards curing below the belt cancers to help patients live well, for longer.

Pelican Cancer Foundation Collection Pots

by

Could you help by hosting a collection pot for Pelican? Our collection pots can hold up to £60 in small change. Small change that can make a big difference to our cause! If you run a business in the local area to Basingstoke and you would be interested in having a collection pot – please contact us by email or call our office on 01256 314746.

Stay in touch to change lives

by

Would you like us to contact you in the future? Under new Data protection rules we will not be able to contact you unless you allow us to. If you are happy to hear about Pelican’s work and events in the future please take a moment to fill in the form below.

The SPECC National Development Programme has successfully completed

by

Significant Polyps and Early Colorectal Cancer – SPECC

Thanks to excellent guidance from our steering group we started the SPECC National Development Programme workshops in London in November 2015.  Since then we have run 14 more workshops across England, Wales, Scotland and Ireland – making it an international programme.

The aims of the programme were to:

  • Define a significant polyp and identify an early colorectal cancer
  • Recognise a SPECC and how this is best achieved
  • Document and describe SPECC to better aid multi-disciplinary decision making
  • Plan carefully – ‘think twice and cut once’, making sure that the first shot it the best as these are ‘high value lesions’. Careful decision making about the use of biopsy and whether they add value. Take time and use regional and national resources, refer to experts – ‘another day, another endoscopist, another hospital’
  • Treatment – first treatment gives the best outcome. Low risk lesions can be safely removed endoscopically. MDT decision must include expert endoscopist

There was a core faculty of 10 with another 90 specialists joining the SPECC faculty to help with presentations and case studies.

1,237 clinicians attended a workshop over the 25 months that the programme ran.  These people came from 178 hospitals in England, Wales, Scotland, Northern Ireland and Ireland.  A third of those attending were consultant surgeons.

The programme was free for 6 core members of each colorectal MDT as long as this included a surgeon, gastroenterologist, pathologist, radiologist and specialist nurse.

Feedback:

‘Very interesting, well organised, fascinating’

‘Very high standard of talks & discussion’

‘Imaging and precision improves definitive treatment’

‘Think twice, cut once’

‘Super informative day – well done Pelican’

‘This was an excellent meeting and a lot of very interesting topics – valuable information for MDT management’

‘More awareness of polyp presentation and input of MDT in management decisions’

Achievement

Nearly every hospital throughout the UK and Ireland has now spent time considering this small but challenging cohort of patients who present with SPECC.  The multi-disciplinary members of the MDT have a greater awareness of the difficulties and uncertainties that SPECC present and will have more confidence within their MDT discussion about the local treatments available and where to refer if need be.

Finally – we would like to thank everyone for their help.  This programme was supported mainly by the generosity of Pelican charitable donations. We are very grateful for industry sponsorship – Norgine supported all of the workshops, Exact Sciences, Medtronic and Applied Medical also attended a small number of meetings.

Publication

Following the completion of the SPECC programme, we were delighted to work with members of the Faculty to compile a supporting supplement for publication – https://onlinelibrary.wiley.com/toc/14631318/2019/21/S1. The publication is 65 pages, made up of 16 supplement articles and the key messages from the Faculty. It is in Free Access format, allowing anyone to view and download the papers, ensuring that the key reference points from the national programme are available for everyone to read.

Pelican Film Society

by

We hold film screenings once a month, from September to July, in the Squire Theatre at The Ark in Basingstoke.

Started in 2003, the Pelican Film Society shows films which either never made it to Basingstoke, or which came and went too quickly for most of us to see. It’s a great opportunity to see recent, art-house and classic films on the huge screen at The Ark Conference Centre.

Even better, it is all in support of a great cause, as all profits from the screenings go to Pelican Cancer Foundation to fight below the belt cancers. The charity is dedicated to improving survival and quality of life for bowel, bladder, prostate and secondary liver cancer patients. Since its inauguration, the Film Society has raised over £18,000 for the charity to help improve treatment for below-the-belt cancers through research and education for cancer specialists.

Renewals for 2018/19 – please click here for a form you can print out and return to us to renew your subscription. Alternatively, you can call us on 01256 314746 to make your annual payment.

Programme 2018

Darkest Hour – September 3rd 

3 Billboards outside Ebbing, Missouri – October 3rd

Phantom Thread – November 5th

Secret Life of Bees – December 3rd

Join Now

Annual Membership for the Film Season 2018/19 is £49.00 for 11 films. Pro rata membership rates are also available. This can be paid by cheque to the Pelican Film Society. Please click here to download the membership form.

Guest Tickets are £6 per person per film and can be paid in cash or by cheque on the night of the screening.

Get your monthly Film Screening Reminders

Sign up to our monthly email to receive screening reminders the week before each screening and be notified of any updates to the film programme. Simply subscribe to the Pelican Film Society emails via subscribe@pelicancancer.org.

(If you change your mind, you can update your marketing preferences at any time by contacting us on unsubscribe@pelicancancer.org.)

Getting there & parking

The Squire Theatre
The Ark
Dinwoodie Drive
Basingstoke
RG24 9NN

Free parking in The Ark’s car park (opposite The Ark Conference Centre).

Why not come early and have some food before the film? From 6pm, The Ark’s licensed Blue Café serves light refreshments.

Pelican Film Society
c/o Pelican Cancer Foundation
The Ark
Dinwoodie Drive
Basingstoke
RG24 9NN

T: +44 (0)1256 314 746
E: admin@pelicancancer.org

Fun Run Santas deliver Christmas cheer for Pelican!

by

High winds and driving rain failed to deter over 80 seasonal supporters who pulled on Santa suits to take part in our first ever Festive Fun Run. Breeze FM teamed up with Pelican for the festive fundraiser in War Memorial Park on Sunday, 10 December.

More than £6,500 has been raised from the event to date. Proceeds will fund Pelican’s clinical research into advancing precision surgery in the treatment of bowel, liver, bladder and prostate cancers. Breeze Weekend presenter Andy Green kept the festive spirits high with feel-good tunes and plenty of yuletide fun as participants ran around a 5km or 10 km course after a warm-up by Cormac Lisle-Fenwick from Fitness First.

The Mayor and Mayoress of Basingstoke and Deane, Cllr Paul Frankum and Cllr Jane Frankum, gave the official seal of approval, thanking everybody for supporting the charity and handing out medals to all the runners. Members of Basingstoke and Deane Rotary volunteered as marshals, and family and friends turned out to cheer on the participants.

Sarah Crane, Chief Executive at Pelican Cancer Foundation, praised everybody who took part. “We are delighted to have received such fantastic support from the local community for Pelican’s first Festive Fun Run.

“People of all ages turned out in the rain and mud to support us – they made a spectacular sight running in their Santa suits and certainly put the fun into fundraising. Our thanks to all involved – their support will make a real difference to local people being treated for ‘below the belt’ cancers.”

See you all next year for our 2018 Festive Fun Run!

 

 

 

Can you help?

by

Please consider donating to Pelican Cancer Foundation – our research studies rely completely on donations. Every penny counts and together we can make a difference.

Research: It is vital that we continue to investigate the most effective treatment for today’s cancer patients.  Pelican supports the early stage of research studies – the grit of sand that creates the pearl.  Many of our projects have led directly to changes in clinical practice whilst others have developed into big multi-national trials. Thanks to Pelican’s work thousands of patients are cured of their disease – but there is more to do.

Education: we embed new research and techniques by bringing together experts to discuss changes in practice.  The surgeons who come on our programmes will change their practice when they get back to their hospital, the radiologist who learn about MRI for prostate cancer are likely to identify an aggressive cancer that would be completely missed using current ‘best practice’.

It is impossible to say exactly how many patients our charity touches every year but in the UK 40,000 patients are diagnosed with bowel cancer, 40,000 men with prostate cancer and 10,000 with bladder cancer.  If only 30% have their diagnosis and treatment improved we impact on 30,000 people in the UK every year – and we work worldwide.

We all want the silver bullet that will end cancer, the pill that prevents all tumours developing but this is still unlikely in our lifetime and in the meantime Pelican is a pragmantic and effective charity that makes a difference for today’s patients.

There are many different ways you can support our work:

Pelican’s Christmas Fair a festive triumph!

by

Christmas shoppers found original and thoughtful gifts for everybody at Pelican Cancer Foundation’s popular festive fair this year.

Stylish jewellery, beautiful clothing, bags and accessories, cute childrenswear, hand-crafted tasty treats, and fun and inexpensive stocking fillers were on offer at The Vineyard Hotel and Spa, Stockcross, Newbury, on Monday 4 December.

The annual event attracted more than 500 visitors and raised £10,600. Proceeds will fund Pelican’s clinical research into advancing precision surgery in the treatment of bowel, liver, bladder and prostate cancers.

The festive atmosphere was enhanced by the Horris Hill School choir’s Christmas carols, there was a tombola and plenty of delicious food and drink to enjoy.

The Pelican Christmas Fair is only possible thanks to the fantastic help that so many volunteers give for the day.

Pelican chief executive Sarah Crane said: “Once again, Pelican was delighted to hold our Christmas fair at The Vineyard – and we were thrilled with the support we received in raising vital funding to help people with ‘below the belt’ cancers.

This day would not be possible if we didn’t have so many wonderful supporters – a fabulous committee helped run the day, the stallholders encouraged us to spend money and all the fantastic people who joined us.” We hope to see you all next year!

 

 

 

SPECC Wales – thought provoking network and discussion

by

Our Welsh SPECC workshop was attended by clinicians from all 11 Welsh hospitals that treat bowel cancer patients and many of the speakers also came from Welsh units.

The day went extremely well, this was an ideal opportunity for bowel cancer clinicians from across the principality to network and discuss this challenging topic.  There is clearly a very good and supportive expert cohort that has set up a good referral service for early bowel cancers but not all doctors and nurses were fully aware of this.  The feedback was very good, we asked clinicians if they would make any changes in their clinical practice and whilst some said  ‘We already do much of this in MDT’ the majority talked about changes to the investigations, recognition and treatment they would offer in future – for example – to consider referring to complex polyp MDT and not biopsy routinely.

Overall, we had an excellent day of thought-provoking clinical questions & perspective of surgical colleagues!

Read our interview with Emma Maltby

by

Emma is a Stoma Clinical Nurse Specialist (SCN) at Basingstoke and North Hampshire Hospital and works closely with Pelican.

How does Pelican help you and your colleagues?

With the multi-disciplinary team (MDT) meetings being held in Pelican’s purpose built room, I have exposure to the charities work, keeping me up to date with the latest developments in the innovative research that Pelican supports. I can attend and participate in educational courses that benefit my development as a SCN, which in turn aids the care that I can deliver to my patients. I am also part of Pelican’s faculty and this enables me to explore the care that I provide for patients and this ensures that I keep the service we offer up to date and relevant.

What attracted you to the role of being a SCN and what are the rewards of your job?

I enjoy problem solving and will quite often have to deal with complications with the stoma*, which are impacting quality of life and wellbeing; I feel a real sense of achievement when I can resolve them, enabling the patient to overcome the issue and return to their daily routine. It’s a real privilege being a stoma care nurse; I am involved with the patients at their most vulnerable time, when quite often their world has stopped. They are frequently quite frightened or scared and I follow them through each stage of their treatment, supporting them and their family to manage the best that they can. My job gives me the opportunity to work closely alongside each patient and it is very humbling to know that I have been part of their journey to help towards restoring their quality of life.

*A stoma is an opening that is made on the wall of the abdomen, which allows food waste to pass out of the body to be collected into an external pouch. There are different types of stoma dependant on the treatment each patient undergoes and it may be temporary or permanent.

What does ‘a day in the life of a stoma nurse’ involve?

My day can be quite busy and diverse. It varies from looking at all stages of the patient pathway, from in patients and regular follow ups with patients who have been discharged from hospital, to complex stoma and fistula management and counselling patients who have been told that they need surgery resulting in a stoma. I also see patients with long-term complex issues for example; high stoma output and then I liaise with members of the MDT to formulate a management plan to enable the patient to be cared for in primary care within the community. I also support hospital staff with the management of stoma care with teaching and guidance, so that if a patient with a stoma is admitted to hospital, their needs are met.

What is your role within the MDT and why is it important that a SCN is included?

For each MDT clinicians will meet to have a collaborative discussion about our patients and the joint input will influence the decision making process. As a SCN my main focus is based on the patient’s ability to cope with the type of stoma that may be required. This will be influenced by the patients’ lifestyle, dexterity and the stomas effect on their activities of daily living and quality of life; also with the consideration of stoma reversal and long-term bowel function.

 How do patients react when they need a stoma?

When we are dealing with patients on a cancer pathway it can be quite upsetting for the patient to be informed that they will need a stoma. This is often because they have limited insight into stoma care and have heard or looked at negative information, often on the internet or social media. As SCN’s we have a lot of clear information about stomas from our industry partners and charities such as the Pelican Cancer Foundation, which assists us in giving details in a manageable and appropriate way. We also sign post patients to stoma support groups where they are able to gather more information and have the opportunity to meet and talk to other stoma patients. As a SCN I can’t alleviate everyone’s fears and anxieties, however just by talking through aspects of stoma care, showing them stoma pouches, the products and how they work, for example, filters so that they know that they won’t smell, can commonly alleviate some of the initial anxieties that the patients will have. We will also discuss their lifestyle and how a stoma will fit in with their everyday life – that they will still be able to work, enjoy leisure activities such as swimming and go about their normal day – with very little limitation and concern about the stoma being noticeable or problematic. My role is based on building a strong and trusting rapport with each patient so that I can knowledgeably inform them about all of the options, which helps them to make an informed decision about their care.

Pelican 25th Anniversary Celebration Dinner

by

 

All the seats for our 25th anniversary dinner are now sold out. Tickets to the drinks reception, plus talks with William Boyd and Professor Heald are still available.

Dress code will be smart with a touch of silver.

Itinerary:

18.30 Drinks reception

19.15 Talk by Professor Heald

19.45 Hannah MacInnes in conversation with William Boyd

20.30 Dinner

22.30 Carriages

We are holding this event at The Pavillion, The Ark, Basingstoke, RG24 9NN.

Tickets for the drinks reception and talks are £50. Please note that these do not include the dinner.

Book your place

Booking form

If you wish to be added to the waiting list for the dinner then please contact events@pelicancancer.org or call 01256 314746

Join us on what promises to be a fabulous night in aid of Pelican Cancer Foundation. We look forward to seeing you there!

 

 

SPECC

by

Definition, Recognition, Documentation, Treatment and Strategic Planning

 

About SPECC
SPECC | Significant Polyp & Early Colorectal Cancer is a national development programme focussed on the treatment of significant polyps and small (T1) tumours. The programme is being delivered in FREE workshops across England and Wales from 2015 to 2017, helping Colorectal Cancer Multi-Disciplinary Teams (MDTs) deliver consistent treatment options for all patients, wherever they live.

Six core members (inc. surgeon, gastroeneterologist, CNS, radiologist and pathologist) of all colorectal MDTs in England and Wales are being invited to attend a one-day workshop on this complex topic.

 

Aims of SPECC
SPECC will help more patients live better for longer, support local cancer services and provide long-term savings for the NHS. It will advance local and regional practice in the definition, recognition, documentation, treatment and strategic planning for significant polyps and early colorectal cancer.

 

Why and how did we develop the SPECC programme?
Mr Brendan Moran, Consultant Colorectal Surgeon at HHFT Basingstoke, identified the uncertainties and challenges for MDTs discussing SPECC. As the programme developed, these uncertainties became more evident, and we decided that it was a worthwhile topic for a national programme to help colorectal MDTs.

Six graduates from Cranfield University spent a month carrying out a Value Management exercise to identify the key project function for SPECC and provided a full report.

At DDF in 2015, we asked 60 people 4 questions on significant polyp and early colorectal cancer decision-making in their MDT. The replies were:

 

 

From these we felt that SPECC was a worthwhile programme, of interest to the majority of multi-disciplinary colorectal clinicians and could enhance decision-making for patients with SPECC.

Overview of SPECC Workshop Content

 

Roll-Out of SPECC
After nearly a year of planning with an eminent steering group, the programme launched in November 2015, and the SPECC faculty have since run the following workshops alongside local faculty:
• London (London Cancer) 06/11/2015
• Bradford (York & Humber) 22/01/2016
• London (London Alliance) 09/03/2016
• Birmingham (West Midlands) 13/05/2016
• Derby (East Midlands) 13/07/2016
• Basingstoke (Wessex) 14/09/2016

 

Read more about past SPECC workshops

View our upcoming SPECC Workshops

Impact of SPECC
We have contacted MDTs through the Pelican contact list and been able to offer 6 free places for each MDT in England and Wales. 383 people from 64 NHS Trusts have joined us at SPECC workshops to date (August 2016).

From the evaluation of the workshops to date, the most common change that people say they will make following their attendance of SPECC is a change at endoscopy:

  • ‘Drive to improve our selection / management’
  • ‘Look at the detail of polyp characteristics’
  • ‘Think twice before attempting polypectomies’

Secondly, many teams, even those with existing specialist MDTs, said that they would put more emphasis on having a specialist SPECC MDT, to allow for even more focussed discussions.

Thirdly, there was greater awareness of the role of biopsy for SPECC and the potential risks to future treatment options.

Online Resources for Delegates

 

“A word about the extremely important SPECC programme, which I attended recently in Basingstoke. Brendan Moran and his team’s enthusiasm, knowledge and commitment to this programme are extraordinary.”
ACPGBI President 2016-17, Mr Peter Dawson
SPECC Basingstoke 14.9.16

“Excellent day: thought-provoking topics & discussions.”
Delegate at SPECC East Midlands 13.7.16

“Case studies were most useful.”
“Very interesting, well organised, fascinating.”
Delegates at SPECC West Midlands 13.5.16

“Very influential meeting.”
“Excellent workshop with expert speakers.”
Delegates at SPECC York & Humber 22.1.16

 

Funding for SPECC
Funding for the SPECC programme has been the greatest challenge to date. We received generous support from Applied Medical (1st workshop), Exact Sciences (first 4 workshops) and Norgine (first 10 workshops).

We were also fortunate to receive some grants from charitable trusts towards the costs of SPECC.

Otherwise funding has come from charitable donations to Pelican and the charity’s reserves.

If you would like to support this important programme, please contact Pelican

Read more about Partners and Sponsors 

 

SPECC Leads, Steering Group and Faculty

Clinical Lead:
Mr Brendan Moran (Consultant Colorectal Surgeon, HHFT Basingstoke)

 

Other leaders in the field, from hospitals around England and Wales, are helping to develop and deliver the programme:

Local Leads:
Mr Ayan Banerjea (Surgeon, Nottingham)
Mr John Grabham (Surgeon, Surrey and Sussex Healthcare NHS Trust)
Mr Jim Hill (Surgeon, Manchester)
Mr Stephan Korsgen (Surgeon, Heart of England)
Mr Jonathan Robinson (Surgeon, Bradford)
Prof Matt Rutter (Gastroenterologist, University Hospital of North Tees)
Mr Jared Torkington (Surgeon, University Hospital of Wales)
Mr Paul Ziprin (Surgeon, London)

The Steering Group and Faculty:
Dr Richard Adams (Oncologist, Cardiff)
Professor Wendy Atkin (Epidemiologist, Imperial)
Dr Svetlana Balyasnikova (Radiologist, Royal Marsden)
Dr Conrad Beckett (Gastroenterologist, Bradford)
Prof Pradeep Bhandari (Gastroenterologist, Portsmouth Hospital)
Mr Neil Borley (Surgeon, Cheltenham)
Dr Corinne Brooks omega Deville replica (Gastroenterologist, HHFT Basingstoke)
Professor Gina Brown (Radiologist, Royal Marsden)
Mr Wayne Croves (Clinical Nurse Specialist, Nottingham)
Mr Chris Cunningham (Surgeon, Oxford)
Mr Mit Dattani (Pelican Research Fellow)
Dr Amandeep Dhadda (Oncologist, Hull & East Yorkshire)
Dr Sunil Dolwani (Gastroenterologist, Cardiff)
Mrs Sarah Duff (University of South Manchester)
Dr James East (Gastroenterologist, Oxford)
Dr Colm Ford (Radiologist, QE Birmingham)
Dr Ian Geh (Oncologist, Birmingham)
Dr Rob Glynne-Jones (Oncologist, Mount Vernon)
Dr Mark Goldstein (Radiologist, Heart of England)
Ms Donna Kellett (Advanced Nurse Practitioner, Bradford)
Dr Gerald Langman (Histopathologist, Birmingham)
Dr Andy Lowe (Radiologist, Bradford)
Mr Michael Machesney (Surgeon, London)
Dr Brian McKaig (Gastroenterologist, Wolverhampton)
Dr Jamie Mills (Oncologist, Nottingham)
Mr Michael Hershman (Surgeon, Wolverhampton)
Mr Mark Peacock (Surgeon, Gloucestershire)
Dr Andrew Plumb (Radiologist, UCL Hospitals)
Mr Rupert Pullan (Surgeon, Torbay)
Professor Phil Quirke (Pathologist, Leeds)
Prof Krish Ragunath (Gastroenterologist, Nottingham)
Mrs Nicky Richards (Clinical Nurse Specialist, HHFT)
Dr Velauthan Rudralingam (University of South Macnhester)
Professor Brian Saunders (Gastroenterologist, St Marks)
Professor John Scholefield (Professor of Surgery, Nottingham)
Mr Adam Scott (Surgeon, Leicester)
Mr William Speake (Surgeon, Royal Derby)
Mr John Stebbing (Surgeon, Royal Surrey)
Professor Bob Steele (Surgeon, Dundee)
Mr Mark Steward (Surgeon, Bradford)
Dr Alex Stewart (Oncologist, Royal Surrey Hospital)
Prof Arthur Sun-Myint (Professor of Clinical Oncology, Clatterbridge)
Dr Claire Taylor (Nurse Consultant, St Mark’s)
Prof Jan van der Meulen (Epidemiologist, LSHTM, London)
Dr Nick West (Histopathologist, Leeds)
Mr Graham Williams (Surgeon, Wolverhampton)

 

Zone Marketing – Table Football

by

Tim and Catherine from our team had a great day fundraising for Pelican in the Zone Marketing table football competition and £500 was raised! Check out the highlights video from Zone Marketing Global Ltd.

Inspirational fundraising by Intermusica

by

Intermusica’s 2017 Charity Concert held in aid of Pelican Cancer Foundation raised an incredible £2,458.60!

From the Renaissance strains of Monteverdi to the luscious sonorities of Elgar, this concert showcased the unique talents of the Intermusica staff team, along with guest appearances from  esteemed artists.

Highlights included a piece composed by Intermusica’s Head of International Touring, Peter Ansell, as well as a performance of the late Sir Peter Maxwell Davies’ unforgettable Farewell to Stromness by Intermusica Managing Director, Stephen Lumsden. The evening culminated in Brahms’ stunning Geistliches Lied, originally written for choir and organ, and heard in a special arrangement for string orchestra and choir by Sir John Eliot Gardiner.

Intermusica were joined by a number of representatives, including Pelican CEO Sarah Crane and Head of Community Fundraising, Tim Lockwood.

View photographs from the evening on Flickr.

Thank you so much to Intermusica for a wonderful year of fundraising events in aid of Pelican Cancer Foundation!

Natasha – Tough Mudder 2017

by

Natasha  decided to raise money for Pelican due to her father’s cancer diagnosis and subsequent major operations and chemotherapy.  Natasha and team completed Tough Mudder for Pelican in September, raising a fantastic £1,130 for the charity.

Thank you!

  

Carys – Cardiff Half Marathon

by

First-time half marathon runner Carys smashed her fundraising target by 340% when she sprinted to success for Pelican Cancer Foundation.

She was delighted to raise £2,550 for the Basingstoke charity by competing in the Cardiff half marathon after a family member was diagnosed with the rare cancer of the appendix, Pseudomyxoma Peritonei.

Carys and her family were moved by the positivity and kindness of the team of doctors and nurses at Basingstoke Hospital who provided great support during their loved one’s treatment.

“Our family member had a life-changing operation at Basingstoke, one of only two hospitals in the UK that specialises in the illness which is very stubborn to treat with chemotherapy,” she said.

“It was a very emotional time and our family pulled together. During the five weeks he was in hospital I always tried to be positive, but it was hard at times. The day we went to bring him home to recover was a happy day.”

Carys’ relative went on to receive chemotherapy in Cardiff and she was inspired to sign up for the city’s half marathon to raise awareness and funds for Pelican, which is dedicated to improving the quality of life for patients with bowel, liver, bladder and prostate cancers.

“I completed the Cardiff half marathon with a time of two hours 13 minutes – I was rather happy and shocked with that time. How I made it the last mile and a half I don’t know! This was a massive achievement for me.

“I was delighted to raise so much money for Pelican as it is a cause close to my heart – the charity’s clinical trials helped with the quick diagnosis of our family member and for that we will always be thankful.”

Pelican chief executive Sarah Crane said: “Congratulations to Carys for completing the Cardiff half marathon and huge thanks to her for raising these much-needed funds for Pelican.

 

 

IMPACT for Greater Manchester – 23rd November

by

Pelican Cancer Foundation invites MDT members to join us at our IMPACT workshop on 23rd November. To be held at LifeCentre, Sale, Manchester. We offer 7 free places per MDT, any additional places will be charged at £95 per person. Unfortunately, we are unable to accept individual registrations.

To book your place, please return your IMPACT Booking Form to courses@pelicancancer.org 

Alternatively – you can post it to us at:

Pelican Cancer Foundation

The Ark, Dinwoodie Drive

Basingstoke

RG24 9NN

We look forward to seeing you there!

 

IMPACT for North East – 17th September

by

Pelican Cancer Foundation invites MDT members to join us at our IMPACT workshop on 17th September. To be held at the Royal Victoria Infirmary Education Centre, Newcastle. We offer 7 free places per MDT, any additional places will be charged at £95 per person. Unfortunately, we are unable to accept individual registrations.

To book your place, please return your IMPACT Booking Form to courses@pelicancancer.org 

Alternatively – you can post it to us at:

Pelican Cancer Foundation

The Ark, Dinwoodie Drive

Basingstoke

RG24 9NN

We look forward to seeing you there!

IMPACT for South East – 29th June

by

Pelican Cancer Foundation invites MDT members to join us at our IMPACT workshop on 29th June. We offer 7 free places per MDT, any additional places will be charged at £95 per person. Unfortunately, we are unable to accept individual registrations.

To book your place, please return your IMPACT Booking Form to courses@pelicancancer.org 

Alternatively – you can post it to us at:

Pelican Cancer Foundation

The Ark, Dinwoodie Drive

Basingstoke

RG24 9NN

We look forward to seeing you there!